Navigation Links
Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
Date:8/30/2012

SAN DIEGO, Aug. 30, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the below listed investor conferences in September. The presentations will include an overview of the Company and an update on recent business activities.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

  • R.W. Baird Health Care Conference on Wednesday, September 5, 2012 at 3:05 p.m. Eastern Time at the New York Palace in New York.
  • Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 11, 2012 at 3:00 p.m. Eastern Time at the Grand Hyatt in New York.
  • G9: ThinkEquity Annual Growth Conference on September 12, 2012 at 10:15 a.m. Eastern Time at Le Parker Meridien in New York.
  • UBS Global Life Sciences Conference on September 19th, 2012 at 8:30 a.m. Eastern Time at the Grand Hyatt in New York.

Live audio webcasts of the presentation may be made accessible on the Investors page of the Company's website at www.optimerpharma.com.  Presentation replays are available at the same location for 90 days following the presentation.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™. The company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-964-3418

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
2. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
3. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
4. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
5. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
6. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
7. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
8. Global RFID in Healthcare and Pharmaceuticals Industry
9. Isis Pharmaceuticals to Present at the 2012 Stifel Nicolaus Healthcare Conference
10. MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock
11. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 26, 2016 According to a new ... Market - U.S. Industry Analysis, Size, Share, Growth, Trends, and ... the U.S. was valued at US$ 5.89 Bn in 2014 ... from 2015 to 2023 to reach US$ 7.99 Bn in ... and emerging needle free drug delivery devices and the market ...
(Date:5/26/2016)... 26, 2016 TARE (Transarterial ... Cost Savings and Overall Decreased Use of ... an international specialist healthcare company, has today announced ... Annual Meeting of ISPOR (International Society for Pharmacoeconomics ... carcinoma (HCC) using yttrium-90 glass microspheres is associated ...
(Date:5/26/2016)... , May 26, 2016 ... has matured into an essential life science tool for ... development applications. BCC Research reveals in its new report ... second growth phase, one powered by a range of ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
Breaking Medicine Technology:
(Date:5/31/2016)... PA (PRWEB) , ... May 31, 2016 , ... More ... Philadelphia, Hep B United Philadelphia, and the Prevent Cancer Foundation held an event on ... silent epidemic in the city of viral hepatitis, the leading cause of liver cancer. ...
(Date:5/31/2016)... ... May 31, 2016 , ... Splashtop Inc., the worldwide leader in ... Networks Co., the leading provider of secure mobile remote access solution for Japan ... leading CACHATTO remote access solution. Splashtop for CACHATTO will be available as ...
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices ... But this approach has proven transformative, both for people who hear voices and for ... is used around the world, but it still lags in the United States. , ...
(Date:5/31/2016)... ... May 31, 2016 , ... When ... he knew it was something that contractors should have at their disposal on ... gets,” says Butch, CertainTeed’s Director of Contractor Programs. , As a result, ...
(Date:5/31/2016)... ... May 31, 2016 , ... CallTrackingMetrics's software ... campaigns, to monitor the performance of sales and support staff, and to efficiently ... The software allows customers to record, transcribe, route, document, and report on everything ...
Breaking Medicine News(10 mins):